747 jili games

As fans eagerly await the release of "Black Myth: Wukong" and the limited edition cola featuring G.E.M., one thing is certain: this collaboration represents a powerful convergence of art, culture, and entertainment that is bound to resonate with audiences around the world. By embracing creativity, diversity, and storytelling, G.E.M., "Black Myth: Wukong," and the cola brand have successfully created a visual and cultural tapestry that captivates the imagination and leaves a lasting impression on all who encounter it.( MENAFN - financial News Media) FN media Group Presents USA News Group News Commentary Vancouver, BC – December 20, 2024 – USA News Group – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights , underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases . This unsettling trend comes as the medical community grapples with the lingering effects of the COVID-19 pandemic. A recent Nature article revealed how disruptions in cancer care-particularly delays in screenings, diagnoses, and treatments-have likely exacerbated the progression of advanced disease, diminished survival rates, and complicated long-term data analysis. Still, the oncology field continues to push forward with promising developments emerging from key innovators like O ncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Cardiff Oncology, Inc. (NASDAQ: CRDF), Personalis, Inc. (NASDAQ: PSNL), Tempus AI, Inc. (NASDAQ: TEM), and Checkpoint Therapeutics, Inc. (NASDAQ: CKPT). The article continued: Additionally, the American Cancer Society has spotlighted an alarming rise in cancer incidence and mortality among younger age groups. Analysts at Exactitude Consultancy anticipate that the global Cancer Immunotherapy Market will expand at a robust 12.84% CAGR, reaching $258.22 billion by 2031 -a clear indicator of oncology's rapid growth and critical importance. Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) , a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers, which were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025. “We are enthusiastic about pelareorep's applicability across multiple gastrointestinal cancer indications, including pancreatic and anal cancer,” said Tom Heineman, M.D., Ph.D., Chief Medical Officer of Oncolytics .“Pelareorep engages patients' immune systems to help make commonly used chemotherapies and checkpoint inhibitors, such as atezolizumab, more effective in fighting cancer. This offers the promise of delaying disease progression and improving survival in patients with these devasting diseases. Given the versatility of pelareorep, we see multiple clinical and regulatory options for bringing this promising medicine to patients.” Oncolytics will present two key data sets from the GOBLET study, with preliminary safety and tumor response results for the relapsed anal carcinoma cohort treated with pelareorep and atezolizumab presented in Poster Session C on January 25, 2025, from 7:00 to 7:55 a.m. PT. Additionally, results from the safety run-in phase for first-line metastatic pancreatic ductal adenocarcinoma patients treated with pelareorep, modified FOLFIRINOX, with and without atezolizumab will be presented in Poster Session B on January 24, 2025, from 11:30 a.m. to 1:00 p.m. PT. Both abstracts will be available on the ASCO Gastrointestinal Cancers Symposium website at 5:00 p.m. ET on January 21, 2025. CONTINUED... Read this and more news for Oncolytics Biotech at: In other recent industry developments and happenings in the market include: Cardiff Oncology, Inc. (NASDAQ: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, recently announced positive initial data from CRDF-004, a randomized, Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). Efficacy and safety data are for all evaluable patients as of a November 26, 2024, data cut-off date, and all efficacy data are determined by a blinded, independent central review (BICR) of each patient's tumor scan. “We are highly encouraged by the robust efficacy signal and favorable safety profile observed with onvansertib plus standard-of-care from the first 30 evaluable patients in our randomized first-line RAS-mutated mCRC CRDF-004 trial,” said Fairooz Kabbinavar, MD, FACP, Chief Medical Officer of Cardiff Oncology .“Our data shows an objective response rate of 64% in patients receiving the 30 mg dose of onvansertib in combination with standard of care, significantly higher than the 33% objective response rate observed in the control arms of standard of care alone. In addition, as can be seen in the spider plots, we are observing deeper tumor response in patients receiving the 30mg dose of onvansertib compared to those receiving the 20mg dose with similar safety profiles for both doses.” Personalis, Inc. (NASDAQ: PSNL), a developer of advanced cancer genomic tests and analytics, and Tempus AI, Inc. (NASDAQ: TEM), an AI-powered healthcare technology company, recently announced they've expanded their commercial relationship. Both companies agreed in November 2023 to collaborate and bring ultra-sensitive MRD testing to market and launched their efforts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Tempus is serving as the exclusive commercial diagnostic partner for Personalis' ultra-sensitive tumor-informed MRD product, NeXT Personal® Dx, for broad patient adoption in breast and lung cancers, and for immunotherapy monitoring across all solid tumors. “While we already offer NeXT Personal through our own biopharma channel, we are pleased to leverage Tempus' integrated platform as well for these biopharma customers who desire to combine NeXT Personal with other Tempus products,” said Chris Hall, CEO of Personalis .“We believe the expansion of the relationship with Tempus will accelerate market penetration of our leading ultra-sensitive MRD platform and allow us to better capitalize on the opportunity.” Under this expanded relationship, Tempus will be enabled to offer Personalis' NeXT Personal MRD product to pharmaceutical and biotech customers who wish to bundle MRD testing with other Tempus offerings in a given study. Checkpoint Therapeutics, Inc. (NASDAQ: CKPT), a commercial-stage immunotherapy and targeted oncology company focused on novel treatments for patients with solid tumor cancers, recently announced that the FDA approved its UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. UNLOXCYT is the first and only programmed death ligand-1 (PD-L1) blocking antibody to receive FDA marketing approval for this indication. “[This] FDA approval of UNLOXCYT – the first marketing approval for our company – is a significant milestone both for Checkpoint and for patients with advanced cSCC,” said James Oliviero, President and CEO of Checkpoin t.“This approval marks Checkpoint's transformation to a commercial-stage company, with the opportunity to compete in a U.S. market estimated to exceed $1 billion annually, where we believe UNLOXCYT offers a differentiated treatment option versus available therapies by binding to PD-L1, rather than programmed death receptor-1 (PD-1), to release the inhibitory effects of PD-L1 on the anti-tumor immune response. Additionally, UNLOXCYT has demonstrated the ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC), another potential differentiating feature of the drug compared to existing marketed therapies for patients with cSCC.” Source: CONTACT: USA NEWS GROUP ... (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. USA News Group is Source of all content listed above. FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein. The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM. FNM is not liable for any investment decisions by its readers or subscribers. FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM was not compensated by any public company mentioned herein to disseminate this press release. This release contains“forward-loking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.“Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as“may”,“future”,“plan” or“planned”,“will” or“should”,“expected,”“anticipates”,“draft”,“eventually” or“projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Media Contact Information: FN Media Group, LLC Media Contact e-mail: ... U.S. Phone: +1(954)345-0611 SOURCE USA News Group MENAFN20122024000225011067ID1109018678 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Firan Technology Group Corporation (TSX: FTG) (OTCQX: FTGFF) ("FTG” or the "Corporation”) is pleased to announce the completion of the previously announced plan of arrangement (the "Transaction”) under the Canada Business Corporations Act pursuant to which FTG has acquired all of the issued and outstanding common shares ("FLYHT Shares”) of FLYHT Aerospace Solutions Ltd. ("FLYHT”). FLYHT is now a wholly-owned subsidiary of FTG. The Transaction was approved at a special meeting held by holders of FLYHT Shares ("FLYHT Shareholders”) on December 16, 2024 by approximately 97.9% of the votes cast by FLYHT Shareholders. Final approval for the Transaction was obtained from the Court of King's Bench of Alberta on December 18, 2024. Under the terms of the Transaction, FLYHT Shareholders were able to elect to receive, in exchange for each FLYHT Share held, (i) CAD$0.1103 in cash and 0.0333 of a common share of FTG (each whole such share, an "FTG Share”), (ii) CAD$0.3379 in cash (the "All-Cash Consideration”) or (iii) 0.0495 FTG Shares (the "All-Share Consideration”), subject to pro-ration (collectively, the "Consideration”). The Consideration is subject to a total maximum cash consideration of CAD$4.3 million and a total maximum share consideration of 1.3 million FTG Shares. As a result of the elections made by FLYHT Shareholders, all FLYHT Shareholders who made an election will receive the following pro-ration: Brad Bourne, President and CEO, FTG stated, "We are thrilled to have successfully completed the acquisition of FLYHT and we are confident that FLYHT will be an important part of FTG's future. As we had previously announced, FLYHT increases our presence in the commercial aerospace aftermarket, and FLYHT's SATCOM product increases our presence on Airbus aircraft, via a licensing arrangement and both of these are strategic priorities for FTG. Going forward we see a path to ramping up sales of FLYHT's product lines and insourcing manufacturing of their product to other FTG sites. We have lots to do, but with the teams at FLYHT and FTG I know we can achieve our goals and create value for our shareholders.” Immediately prior to the effective date of the Transaction, FTG and its subsidiaries did not own any FLYHT Shares. Under the terms of the arrangement, FTG acquired 38,997,650 FLYHT Shares, being all of the issued and outstanding FLYHT Shares. The aggregate consideration to be paid for the FLYHT Shares is approximately CAD$4.3 million and 1.3 million FTG Shares. The closing trading price of an FTG Share on the Toronto Stock Exchange on December 19, 2024, the date immediately prior to the effective date of the Transaction, was CAD$7.28. An early warning report will be filed on SEDAR+ at www.sedarplus.com under FLYHT's profile. In order to obtain a copy of the early warning report, please contact Jamie Crichton, FTG's Vice President and CFO at: (416) 299-4000, ext. 264. ABOUT FIRAN TECHNOLOGY GROUP CORPORATION FTG is an aerospace and defense electronics product and subsystem supplier to customers around the globe. FTG has two operating units: FTG Circuits is a manufacturer of high technology, high reliability printed circuit boards. Our customers are leaders in the aviation, defense, and high technology industries. FTG Circuits has operations in Toronto, Ontario, Chatsworth, California, Fredericksburg, Virginia, Minnetonka, Minnesota, Haverhill, Massachusetts and a joint venture in Tianjin, China. FTG Aerospace designs, certifies, manufactures and provides in-service support for illuminated cockpit products and electronic assemblies for original equipment manufacturers and operators of aerospace and defense equipment. FTG Aerospace has operations in Toronto, Ontario, Calgary, Alberta, Chatsworth, California and Tianjin, China. The Corporation's shares are traded on the Toronto Stock Exchange under the symbol FTG, and on the OTCQX Exchange under the symbol FTGFF. FORWARD-LOOKING STATEMENTS This news release contains certain forward-looking statements. These forward-looking statements are related to, but not limited to, expectations regarding the potential benefits and synergies of the Transaction for FTG, delisting of the FLYHT Shares from the TSX Venture Exchange and FTG's intention to cause FLYHT to cease to be a reporting issuer. Forward-looking information typically contains words such as "anticipate”, "believe”, "expect”, "plan” or similar words suggesting future outcomes. Such statements are based on the current expectations of management of the Corporation and inherently involve numerous risks and uncertainties, known and unknown, including economic factors and the Corporation's industry, generally. The preceding list is not exhaustive of all possible factors. Such forward-looking statements are not guarantees of future performance and actual events and results could differ materially from those expressed or implied by forward-looking statements made by the Corporation. The reader is cautioned to consider these and other factors carefully when making decisions with respect to the Corporation and not place undue reliance on forward-looking statements. Other than as may be required by law, FTG disclaims any intention or obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

On the other hand, the prosecution argued that Sergeant Smith's use of force was unwarranted and constituted a violation of the protester's rights. They pointed to the video evidence, which showed the protester being subdued by multiple officers before Sergeant Smith intervened. The prosecution also highlighted inconsistencies in Sergeant Smith's testimony and raised questions about his motives for using such excessive force.Moreover, Wang Chuqin's statement also sheds light on the mental toughness required to navigate external pressures and maintain composure in the face of adversity. By remaining steadfast in his belief in the integrity of the sport and the systems in place to regulate it, Wang Chuqin demonstrates a maturity and maturity beyond his years, earning him admiration from fans and peers alike.UnitedHealthcare CEO kept a low public profile. Then he was shot to death in New York